Canada Medical Device Licence Registration Service

Scope and evidence must be confirmed before any paid tests or filings.

A Canadian medical device licence registration service should deliver a filing-ready submission and a controlled response process—not an instant approval. Health Canada issues the licence. The first question is whether the transaction concerns a device-specific Medical Device Licence (MDL) or an establishment licence (MDEL). The two are not interchangeable, and Canada applies federal rules nationwide.

Which application must be filed?

Situation	Filing decision and responsible party
Class I manufacturer	No product-specific MDL. Assess whether the manufacturer needs an MDEL based on its distribution route; an exempt arrangement must be documented, not assumed.
Class II–IV manufacturer	The manufacturer named on the label applies for a new or amended MDL covering the appropriate device, family or system. An acceptable MDSAP quality-system certificate and class-specific evidence are prerequisites.
Importer or distributor	Assess the operator’s MDEL obligation separately. An MDEL does not legalize an unlicensed Class II–IV product: check the exact device and manufacturer in MDALL before supply.

An MDEL has its own form and procedure and is outside the MDL Regulatory Enrolment Process (REP). Do not submit an MDEL application using the MDL XML route.

Pre-filing dossier and evidence gate

Resolve these five records before the application is transmitted. A missing item is a stop condition, not something that filing software can fix.

Record	What to check
Manufacturer identity	Legal name and addresses, label manufacturer, manufacturing sites, contact details and company enrolment identifiers must be consistent.
Device scope	Intended use, Canadian risk class, identifiers, models and grouping must align across labels, device details spreadsheet and the requested licence type.
Quality system	A current ISO 13485 certificate issued by an MDSAP auditing organization recognized by Health Canada; verify manufacturer, sites and the scope of design/manufacture for the relevant class.
Safety and performance	Class II relies on specified declarations/attestations and evidence held by the manufacturer; Class III–IV require technical/scientific evidence submitted for review. IVD and special device types may require different content.
Submission package	Use current REP company and dossier identifiers; RT XML and AI XML where required; a device details spreadsheet for new licences and catalogue-impacting amendments; a signed attestation for the initial transaction of a new regulatory activity; fee material and the appropriate IMDRF table-of-contents structure.

Applicant, signatory and correspondent

The legal MDL applicant and licence holder is the device manufacturer, including a foreign manufacturer. A properly designated regulatory correspondent can prepare and transmit the file and manage correspondence but does not become the product manufacturer or guarantee the decision. The manufacturer supplies and validates product evidence and signs the required attestation. The importer/distributor determines its separate MDEL position and verifies the device licence. Assign one owner for responses and document control.

Actual filing sequence through REP and CESG

Confirm the Canadian device classification and whether this is a new MDL, an amendment or a different regulatory route.
Complete or update REP company (CO) enrolment: email the draft CO XML to Health Canada and obtain the validated final CO XML with the company and contact IDs before filing the regulatory transaction.
If no dossier ID exists, submit the dossier ID request form and obtain the ID from Health Canada. For an existing dossier, retrieve its correct ID; never reuse an unrelated dossier number.
Compile class-specific evidence and fee information in the prescribed folder structure. Include the device details spreadsheet for a new licence or a catalogue-impacting amendment, and the signed attestation for the initial transaction of a new regulatory activity.
Generate the required final REP XML files (RT and AI where applicable). Do not include superseded Class II–IV PDF licence forms alongside REP XML.
Transmit the complete regulatory transaction via the Common Electronic Submissions Gateway (CESG), preserving acknowledgement and version history.
Triage screening questions and additional-information letters; send indexed, evidence-linked responses through the specified REP/CESG route, then record the decision.

Causes of screening delays or rejection

A Canadian class or application type chosen only from an EU/FDA classification.
Device identifiers, labels, company profile and spreadsheet describing different manufacturers or models.
Missing, expired or improperly scoped MDSAP certificate; missing scientific support for Class III–IV.
Incorrect dossier/transaction identifiers, folder conventions, fee documents or blocked attachments.
Slow or incomplete replies to deficiency letters. The official response window depends on the letter and stage; never treat it as an informal extension.

Decision gates, fees and realistic timing

Health Canada first screens administrative and regulatory completeness; Class III–IV also undergo technical screening and substantive review. Published performance targets include 15 calendar days for the first Class II screening decision after receipt of an administratively complete application, and 60/75 calendar days for the first Class III/IV review decision after screening acceptance. These are stage targets, not promised end-to-end clearance dates; questions and applicant response time add delay. Published application fees effective 1 April 2026 include CAD 643 (standard Class II), CAD 14,163 (standard Class III) and CAD 30,713 (standard Class IV); other categories and mitigation rules differ. Budget separately for audits, specialist evidence, filing work and subsequent annual fees.

What must happen after the decision?

Check the issued MDL’s device/manufacturer scope and MDALL record before distributing covered devices.
Track the manufacturer’s annual MDL renewal notification before 1 November and the applicable annual right-to-sell fee; this is separate from any MDEL annual review before 1 April.
Control intended-use, design, manufacturing and label changes; certain Class III–IV significant changes require an MDL amendment before implementation.
Maintain complaint, incident, recall and distribution-traceability processes according to the roles and applicable regulations. An MDL is not an exemption from post-market duties.

Registration service deliverables and handover

A properly scoped filing engagement can cover an intake/route memo, a gap list assigned to evidence owners, the assembled REP-ready submission, transmission records and an authority-question tracker. The final handover should identify the licence and version, outstanding conditions, renewal dates and change-control owner. Device testing, MDSAP certification and Health Canada approval are separate activities or decisions unless expressly included and completed.

For classification strategy see medical device licence consulting; for related licensing coverage see medical device licensing services; and for the wider Canadian compliance landscape see Canadian product compliance and market access.

Filing FAQ

Can my Canadian distributor apply for the manufacturer’s MDL?: No. The MDL is issued to the manufacturer. A distributor may need its own MDEL; neither registration replaces the other.
Does a Class I device need an MDL number?: No Class I product MDL is required. Check the manufacturer’s sales route and any applicable MDEL requirements and exemptions before launch.
Will a general ISO 13485 certificate suffice?: Not for an ordinary Class II–IV MDL if it is not an acceptable MDSAP certificate issued by a Health Canada-recognized auditing organization with the correct scope.
Does existing EU CE marking or US FDA clearance remove the Canadian filing?: No automatic substitution. The Canadian device class, application and supporting evidence must be assessed independently.
Can we ship while the licence application is under review?: An ordinary Class II–IV application does not itself permit import or sale; use only a separately valid statutory authorization or exception where specifically applicable.
Should we still attach the old MDL application PDF to REP XML?: No. For covered Class II–IV transactions the REP XML replaces the legacy licence application forms; filing them together can cause rejection.